Top-News

ATyr Pharma Aktie News

Aktie
WKN:  A2PM86 ISIN:  US0021202025 US-Symbol:  ATYR Branche:  Biotechnologie Land:  USA
0,71 €
+0,00 €
0,00%
10:44:01 Uhr
Depot/Watchlist
Marktkapitalisierung *
57,55 Mio. €
Streubesitz
33,11%
KGV
-4,70
Index-Zuordnung
-

ATyr Pharma News

20.10.25 - PR Newswire
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR PR Newswire
20.10.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
18.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR PR ...
17.10.25 - PR Newswire
aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR
aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR PR Newswire
17.10.25 - PR Newswire
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman PR Newswire
17.10.25 - PR Newswire
Contact Levi & Korsinsky by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc.(ATYR)
Contact Levi & Korsinsky by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc.(ATYR) PR Newswire
16.10.25 - PR Newswire
The Gross Law Firm Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
The Gross Law Firm Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR PR Newswire
15.10.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit PR Newswire
15.10.25 - PR Newswire
ATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
ATYR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma PR Newswire
14.10.25 - PR Newswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...
14.10.25 - PR Newswire
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman PR Newswire
13.10.25 - PR Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire
10.10.25 - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit PR Newswire
10.10.25 - PR Newswire
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company PR Newswire
09.10.25 - PR Newswire
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman PR Newswire
08.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR PR Newswire
03.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR PR Newswire
28.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR PR Newswire
23.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR PR Newswire
23.09.25 - PR Newswire
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »